B of A Securities Maintains Underperform on Enfusion, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Koji Ikeda has maintained an Underperform rating on Enfusion (NYSE:ENFN) and raised the price target from $8 to $9.

March 13, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Enfusion's Underperform rating is maintained by B of A Securities, but the price target is increased from $8 to $9.
The adjustment in price target by B of A Securities suggests a slightly more optimistic outlook on Enfusion's financial performance or market position. However, the maintenance of an Underperform rating indicates that the analyst still sees challenges ahead for the company that may hinder its stock performance in the short term. The increase in price target could lead to a mixed reaction in the market, with some investors seeing it as a positive sign, while the Underperform rating could temper expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100